---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-052344"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2023-02-28T23:59:59+00:00"
generated_at: "2026-06-18T22:28:50.868208+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Phathom reports Q4 net loss $55M; FDA meeting in March for vonoprazan resubmission

## Summary
- Net loss Q4 2022 $55.0M vs $35.8M Q4 2021; full year net loss $197.7M vs $143.9M.
- Cash $155.4M at Dec 31, 2022; additional $100M available under Hercules term loan.
- FDA meeting scheduled March 2023 to discuss stability data and resubmission for erosive GERD and H. pylori NDAs.
- Positive Phase 3 PHALCON-NERD-301 met primary endpoint (p<0.0001) for vonoprazan in non-erosive GERD.
- Commercial launch on hold due to nitrosamine impurity; mitigation measures in place.

## SEC filing metadata
- accession: 0001193125-23-052344
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2023-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312523052344/0001193125-23-052344-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312523052344/d413841d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-052344
- JSON: https://secwatch.observer/filing/0001193125-23-052344.json
- Plain text: https://secwatch.observer/filing/0001193125-23-052344.txt

## Key facts
- Earnings Releases
  Phathom Pharmaceuticals, Inc. reported the quarter and year ended December 31, 2022 results: net income Net loss for the fourth quarter ended December 31, 2022 was $55.0 million.
  - Period: the quarter and year ended December 31, 2022
  - Net income: Net loss for the fourth quarter ended December 31, 2022 was $55.0 million
  - Result: reported results
  source text: On February 28, 2023, Phathom Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312523052344/0001193125-23-052344-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.